Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 5/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828543 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL536928 | 0.92 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL537177 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL3552863 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL20026414 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL2998889 | 0.88 | NPSR1 (0.51) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL3552861 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL2989249 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL3792356 | 0.87 | NPSR1 (0.52) | SMN1; SMN2LMNAKMT2ANPSR1MAPT | |
| SCHEMBL20026415 | 0.86 | PDE4B (0.48) | SMN1; SMN2LMNAKMT2ANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1606256-B1 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | CELGENE CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7799819-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-7662847-B2 | Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors | CELGENE CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7511072-B2 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION. | 2007-11-01 | — | — | US | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7034052-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MAN HON-WAH | 2006-03-16 | — | — | US | disclosed |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | AMGEN INC. | 2005-09-15 | — | — | US | disclosed |
| US-6911464-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | AMGEN INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MCL1, APC, HPGDS | SMN1; SMN2 203/4885LMNA 369/4885KMT2A 3209/4885 |
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE12, PDE4B | SMN1; SMN2 1341/4885LMNA 859/4885KMT2A 2324/4885 |
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | MCL1, APC, THPO | SMN1; SMN2 242/4885LMNA 397/4885KMT2A 3941/4885 |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | PDE4A, PDE4B, PDE7A | SMN1; SMN2 1200/4885LMNA 819/4885KMT2A 2008/4885 |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | PDE4A, PDE12, PDE4B | SMN1; SMN2 1341/4885LMNA 859/4885KMT2A 2324/4885 |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | MCL1, THPO, APC | SMN1; SMN2 274/4885LMNA 1288/4885KMT2A 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.